TIRZEPATIDA· 20 MG/3 ML · VIAL MULTIDOSIS | GIP/GLP-1, Reducción de peso, control glucémico y mejora marcadores metabólicos

Key Benefits of Tirzepatide Dual GIP/GLP-1 Agonist for Advanced Research Tirzepatide is a synthetic research peptide that acts as a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual activation provides a synergistic effect that potentiates glycemic control and promotes weight reduction. Synergistic Incretin Receptor Activation Tirzepatide binds and simultaneously activates both GIP and GLP-1 receptors, which are key in regulating glucose homeostasis. GLP-1 activation stimulates insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite. GIP, in turn, potentiates insulin secretion, improves insulin sensitivity in adipose tissue and skeletal muscle, and reduces ectopic fat accumulation. The combination of both agonists provides an additive and synergistic effect that surpasses single receptor agonists. Advanced Metabolic Research Tirzepatide enables the study of dual agonist mechanisms in glucose metabolism, appetite regulation, and body composition. Its efficacy in weight reduction and glycemic control has been demonstrated in clinical trials, with weight reductions of up to 22.5% over 72 weeks and a risk reduction of progression to type 2 diabetes of up to 93%. Cardiovascular and Renal Research Applications Emerging evidence suggests that tirzepatide may confer cardiovascular and chronic kidney disease benefits. Research studies are exploring these effects through mechanisms involving improved endothelial function, reduced inflammation, and blood pressure modulation. Longevity and Neuroprotection Research Emerging evidence suggests that GLP-1 agonists may have neuroprotective and mental health effects. Incretin pathway modulation has been shown to influence cellular signaling related to aging and tissue regeneration in animal models. Hepatic and Metabolic Health Tirzepatide has been observed to improve hepatic steatosis and inflammatory responses in preclinical models. Recent clinical studies have demonstrated significant resolution of metabolic dysfunction-associated steatohepatitis (MASH) without worsening of fibrosis. High Purity and Pharmaceutical Quality Research-grade peptide with ≥98% purity. Formulation in a 3 mL multi-dose vial with 20 mg/mL concentration. Research dosing: 5 mg = 0.75 mL. Recommended storage between 2°C and 8°C. Protect from light. Do not freeze. For Research Use Only Product intended exclusively for research (Research Use Only). Not approved for human or veterinary use.

Function and Mechanism of Action of Tirzepatide Tirzepatide is a synthetic 39-amino acid peptide that acts as a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Its chemical name is Tirzepatide and its CAS number is 2023788-19-2. Its sequence includes two non-natural aminoisobutyric acid (Aib) residues at positions 2 and 13, which confer resistance to proteolytic degradation and an extended half-life. Detailed Mechanism of Action: Molecular Structure: Tirzepatide is a 39-amino acid peptide with a molecular weight of approximately 4813 g/mol and molecular formula C₂₂₅H₃₄₈N₄₈O₆₈. Its sequence includes two non-natural aminoisobutyric acid (Aib) residues that confer resistance to proteolytic degradation, extending its half-life and enabling weekly dosing in studies. The peptide possesses a modification at residue Lys20 with a C20 fatty acid side chain that improves serum albumin binding and prolongs its action. GLP-1 Receptor Activation: Tirzepatide binds to the GLP-1 receptor with high affinity, activating the cAMP signaling pathway. This stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, delays gastric emptying, and reduces appetite through central effects in the hypothalamus. GLP-1 receptor activation has also demonstrated cardioprotective, neuroprotective, and anti-inflammatory effects in research studies. GIP Receptor Activation: Tirzepatide also binds to the GIP receptor, activating additional signaling pathways through the AKT/PKB pathway. GIP potentiates glucose-dependent insulin secretion, improves insulin sensitivity in adipose tissue and skeletal muscle, promotes lipid storage in white adipose tissue, and reduces ectopic fat accumulation in muscle. GIP also has effects on appetite and satiety, although the precise mechanisms are still being investigated. GIP/GLP-1 Synergy: Simultaneous activation of both receptors produces a synergistic effect that potentiates glycemic control and promotes greater weight reduction compared to single receptor agonists. GIP potentiates GLP-1 effects, leading to tirzepatide being proposed as a &amp;quot;super-GLP-1&amp;quot;. Evidence suggests that GIP may potentiate GLP-1&amp;#039;s anorectic effects and improve insulin sensitivity. Brown Adipose Tissue: 2026 evidence suggests that tirzepatide may also activate brown adipose tissue, increasing energy expenditure at the tissue level. Route of Administration and Research: Tirzepatide is administered subcutaneously in research studies. The 3 mL multi-dose vial with 20 mg/mL concentration facilitates dosing under multiple experimental conditions. Research dosing: 5 mg = 0.75 mL. Storage: Preferably store between 2°C and 8°C (refrigeration). Do not freeze. Protect from light. Research Quality: Research-grade peptide with ≥98% purity. Manufactured under strict quality control standards. Research Use Only.

How to Use Tirzepatide Route of Administration: Subcutaneous (for research). Tirzepatide is administered subcutaneously in research studies. For research use only by qualified personnel in laboratory settings. Dosage: Dosage should be determined according to the specific research protocol and experimental conditions. General dosage guidelines for tirzepatide in research include: Research Ranges: Research studies have used weekly doses that vary according to the experimental model and study objectives, ranging from 2.5 mg to 15 mg weekly. Research Dosing: 5 mg = 0.75 mL (for standardized protocols). Frequency: Weekly administration in research studies, due to the peptide&amp;#039;s extended half-life. Treatment Duration: Treatment duration in research studies varies according to experimental design, from acute studies to long-term studies of 72-176 weeks. Storage: Preferably store between 2°C and 8°C (refrigeration). Do not freeze. Protect from light. Keep out of reach of children. Multi-Dose Vial Instructions: This product is a multi-dose vial designed to contain more than one research dose. It is recommended to: - Use the vial only in a clean, designated area for injection preparation. - Clean the vial stopper with an alcohol pad before each use. - Use new sterile needles and syringes for each withdrawal. - Label the vial with the opening date and time. - Discard the vial within 28 days of opening, unless the manufacturer specifies a different period. - Never combine partial doses from multiple vials. Important Notice: Product intended FOR RESEARCH USE ONLY. Not approved for human use, diagnosis, treatment, or prevention of disease. Do not exceed the doses specified in the research protocol. Consult with a principal investigator or ethics committee before starting any research.

Ingredients of Tirzepatide Composition per mL: Active Ingredient: Tirzepatide: 20 mg CAS Number: 2023788-19-2 Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈ Molecular Weight: ~4813 g/mol Sequence: Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-C20-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ Vehicle: Water for Injection: Sterile vehicle for the formulation. Excipients: The formulation may contain additional excipients such as buffering agents, preservatives, and stabilizers to ensure peptide integrity and formulation stability (consult the product leaflet for the complete list of ingredients). Note for Users: This product is a research-grade peptide manufactured under strict quality control standards. Each vial contains 3 mL of solution, with a concentration of 20 mg/mL. Research dosing: 5 mg = 0.75 mL. Preferably store between 2°C and 8°C. Do not freeze. Protect from light. Research Use Only.

Onset Time &amp;amp; Expected Results of Tirzepatide Onset of Action (Hours to Days): In research studies, tirzepatide begins to exert its effects within the first hours after subcutaneous administration. Activation of GLP-1 and GIP receptors stimulates insulin secretion and suppresses glucagon in response to nutrient intake. Effects on appetite and satiety can be observed within the first days. Evidence suggests that tirzepatide may also activate brown adipose tissue, increasing energy expenditure at the tissue level. Measurable Benefits (Weeks 4-8): The first measurable changes in body weight, glycemic control, and metabolic markers begin to be visible within the first 4-8 weeks of administration in research studies. Studies have demonstrated significant weight reductions in this period, with weight reduction of up to 22.5% over 72 weeks at the 15 mg dose. Full Effect (Weeks 12-24): For maximum benefit in weight reduction, glycemic control, and metabolic effects, the full effect often requires 12-24 weeks of administration in research studies. Clinical trials have demonstrated weight reductions of up to 22.5% over 72 weeks. Projected Results (Research Studies): - Significant weight reduction: Decrease in body weight in study models (up to 22.5%) - Improved glycemic control: Reduction in blood glucose levels (HbA1c reduction of up to 2.24%) - Improved insulin sensitivity: Greater efficiency in glucose utilization - Appetite reduction: Decrease in caloric intake in study models - Improved metabolic markers: Reduction in inflammation and improved lipid profile - Cardiovascular benefits: Reduction in cardiovascular event risk - Hepatic benefits: Resolution of steatohepatitis and reduction of hepatic complications Factors Influencing Results: The speed and magnitude of results depend on dose administered, adherence to the research protocol, experimental conditions, study model, individual metabolism, and genetics.

Clinical Research &amp;amp; 3rd Party Test Results of Tirzepatide Scientific evidence on tirzepatide comes from clinical trials and research studies in metabolism, endocrinology, and cellular biology. Clinical Evidence in Humans: SURMOUNT-1 Trial: The SURMOUNT-1 trial demonstrated that tirzepatide produced weight reduction of up to 22.5% over 72 weeks in adults with obesity or overweight at the 15 mg dose. The study also demonstrated a risk reduction of progression to type 2 diabetes of up to 93%. SURPASS-2 Trial: The SURPASS-2 trial, which compared tirzepatide with semaglutide 1 mg in patients with type 2 diabetes, demonstrated that tirzepatide was superior in HbA1c reduction and weight loss across all doses evaluated (5 mg, 10 mg, 15 mg). SURMOUNT-2 Trial: In adults with obesity and type 2 diabetes, tirzepatide demonstrated weight loss of 12.8% to 14.7% with significant improvements in glycemic control. SURPASS-1 Trial: In treatment-naive type 2 diabetes patients, tirzepatide produced HbA1c reductions of 1.87% to 2.07% versus placebo. 2025-2026 Evidence: Hepatic Health: A 2026 real-world data analysis, including over 54,000 patients, associated tirzepatide use with a 68% lower risk of severe hepatic complications. Clinical studies have demonstrated significant resolution of metabolic dysfunction-associated steatohepatitis (MASH) without worsening of fibrosis. Cardiovascular Health: Clinical trials have demonstrated that tirzepatide reduces heart failure or cardiovascular death events by 38% in patients with preserved ejection fraction. 2026 research indicates its potential to improve outcomes for procedures such as aortic valve replacement. Brown Adipose Tissue: 2026 evidence suggests that tirzepatide may also activate brown adipose tissue, increasing energy expenditure at the tissue level. Safety Considerations: Side Effects in Research: In clinical studies, the most common side effects have been gastrointestinal (nausea, vomiting, diarrhea), generally mild to moderate and transient. Contraindications: Research product. Not approved for human use. Not recommended for individuals with a history of pancreatitis, severe kidney disease, or hypersensitivity to the compound. Regulatory Status: Tirzepatide is approved for clinical use in some countries for the treatment of type 2 diabetes and obesity (Mounjaro, Zepbound). This product is research-grade and is not intended for human use. Quality Standards of Kinetix Smartpharma: Research Grade: Research-grade peptide with ≥98% purity. Manufacturing: Manufactured under strict quality control standards (GMP). Quality Control: Each batch is subjected to quality control testing to ensure purity, potency, and sterility. Note: This product is a research compound and is not intended for human use, diagnosis, treatment, or prevention of disease. Results may vary according to the study model and experimental conditions.

Product Details

TIRZEPATIDA· 20 MG/3 ML · VIAL MULTIDOSIS | GIP/GLP-1, Reducción de peso, control glucémico y mejora marcadores metabólicos

TIRZEPATIDA· 20 MG/3 ML · VIAL MULTIDOSIS | GIP/GLP-1, Reducción de peso, control glucémico y mejora marcadores metabólicos

Build Your Stack

Frequently Asked Questions